Apamistamab
Diffuse Large B-Cell Lymphoma With Chronic Inflammation
Explore 16 assets in Diffuse Large B-Cell Lymphoma With Chronic Inflammation →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
monoclonal_antibody
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04512716CT.gov Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma With Chronic Inflammation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apamistamab (this asset) | Memorial Sloan Kettering Cancer Center | Early P1 | C · 39 |
| Prednisone | Northwestern University | P2/3 | BB |
| Adriamycin | Northwestern University | P2/3 | BB |
| Vincristine Sulfate | Northwestern University | P2/3 | BB |
| Cyclophosphamide | Mayo Clinic | P2/3 | B |
| Rituximab | Mayo Clinic | P2/3 | B |
| Recombinant Human Hyaluronidase | National Cancer Institute (NCI) | P2/3 | B |
| Azacitidine | National Cancer Institute (NCI) | P2/3 | B |
| Pembrolizumab | Mayo Clinic | P2 | CCC |
+7 more in the Diffuse Large B-Cell Lymphoma With Chronic Inflammation cohort
Other indications for Apamistamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P3 | B · 62 |
| Disease Related To Hematopoietic Stem Cell Transplant | — | P3 | B · 60 |
| Myeloid Leukemia | — | P2/3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apamistamab in Diffuse Large B-Cell Lymphoma With Chronic Inflammation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/monoclonal-antibody-bc8-diffuse-large-b-cell-lymphoma-with-chronic-inflammation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →